Scott Haake, MD, PhD, is a kidney cancer-focused investigator and leads a research team focused on tumor cell interaction with the extracellular matrix, integrin signaling, biomarker development, and kidney cancer biology. His work spans multiple projects, including basic cancer biology research, animal models of cancer, translational work in human tissues and clinical trials.
His work is funded by the National Cancer Institute, the Kure It Foundation, and the Department of Defense Kidney Cancer Research Program. As a board-certified medical oncologist, Dr. Haake has a kidney and genitourinary cancer-focused clinic and cares for patients at both Vanderbilt University Medical Center and the Nashville VA Hospital.
Dr. Haake has been awarded Young Investigator Awards by the American Association of Cancer Research (2015) and the Kidney Cancer Association (2019). He has also received a Research Scholars Award from the American Urological Association (2016). In 2008 he was elected to the Alpha Omega Alpha national medical honor society during his junior year of medical school. In 2005, Haake received the King-O'Neal Scholar Award, an award reserved for those graduating first in their class at the University of South Florida.
Dr. Haake has authored or co-authored approximately 20 articles published in the peer-reviewed scientific literature. In addition to his current funding, his research has previously been funded by the Conquer Cancer Foundation, American Urological Association, the Vanderbilt Clinical Oncology Research Career Development Program, the Kidney Cancer Association, and the Vanderbilt Institute for Clinical and Translational Research.
The research program in the Haake lab focuses on studying the role of extracellular matrix (ECM) signaling during tumor initiation and evolution. Our translational and clinical work is focused on biomarker development in kidney cancer and our current research is focused on understanding the biological factors that regulate integrin signaling in various tumor types.